Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Superior Remedies

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Superior Remedies head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 296 · Grade C

Superior Remedies

Visit Superior Remedies Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 62 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Superior Remedies a bad call — it's best for readers who want a low-dose protocol designed on its own terms rather than a smaller version of a weight-loss plan, and who do not mind starting an eligibility check to learn the price. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
40
Supply Reliability
88
65
Transparency
84
30
Access Breadth
82
95
Clinical Oversight
88
80
Track Record
90
55
Invigor MedicalBrief Score 88 · 62Superior Remedies

Price, coverage & the tracker

Invigor MedicalSuperior Remedies
Brief Score88/100 (B+)62/100 (C)
Semaglutide$199/moNot disclosed
Tirzepatide$339/moNot disclosed
CoverageNot disclosedAll 50 states (telehealth nationwide)
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Superior Remedies: New to the tracker on 11 August 2026, read on the provider's own site rather than taken on trust: we loaded https://superiorremedies.com/treatments/glp-1-microdose on 2026-08-11 and it publishes no price and no milligram anywhere on the page. The only figure the public site carries is a homepage headline labeled a limited-time offer, attached to the general pitch rather than to any one of its three programs. There is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.